Despite a surge in FDA-cleared radiology AI tools, very few qualify for reimbursement due to lack of supporting clinical studies.
Key Details
- 1Radiology comprises roughly 80% of all FDA-cleared medical AI algorithms.
- 2Only one CPT category 1 payment code for newer AI tools exists today; a second will be added in January 2026.
- 3Both reimbursement codes are specific to cardiac imaging AI applications.
- 4Hundreds of approved algorithms lack reimbursement due to insufficient clinical evidence of patient benefit.
- 5Experts attribute the problem to a disconnect between regulatory clearance and payment policy.
Why It Matters
Without reimbursement, the financial incentives for clinical adoption of imaging AI are limited, slowing broader deployment of these technologies. Bridging the gap between regulatory approval and payment is critical for real-world impact of AI in radiology.
Source
Radiology Business
Related News
•AuntMinnie
HPI Rebuts AI's Supposed Impact on Radiology Workforce Shortage
Harvey L. Neiman HPI challenges recent claims that AI has lessened the radiology workforce burden, citing evidence of rising workloads and imaging volumes.
•Radiology Business
GE HealthCare Appoints Chief AI Officer to Lead Imaging Innovation
GE HealthCare has hired Rodolphe Katra as its new global chief AI officer to drive its AI strategy in imaging.
•Radiology Business
FDA Authorizations for Radiology AI Devices Surge 42% Since 2023
FDA-cleared radiology AI devices rose by 42% between 2023 and 2025, now totaling over 1,000 approved tools.